Antibody-mediated rejection (AbAR) is increasingly recognized in the renal allograft population, and successful therapeutic regimens have been developed to prevent and treat AbAR, enabling excellent outcomes even in patients highly sensitized to the donor prior to transplant. It has become critical to develop standardized criteria for the pathological diagnosis of AbAR. This article presents international consensus criteria for and classification of AbAR developed based on discussions held at the Sixth Banff Conference on Allograft Pathology in 2001. This classification represents a working formulation, to be revisited as additional data accumulate in this important area of renal transplantation.
Article de périodique (Journal article) – Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.
Publication date
2003
Journal information
"American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons" - Vol. 3, no. 6, p. 708-14 (2003)
Racusen, Lorraine C ; Colvin, Robert B ; Solez, Kim ; Mihatsch, Michael J ; Halloran, Philip F ; et. al. Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection.. In: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, Vol. 3, no. 6, p. 708-14 (2003)